0001493152-23-035700.txt : 20231004 0001493152-23-035700.hdr.sgml : 20231004 20231004171027 ACCESSION NUMBER: 0001493152-23-035700 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231004 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231004 DATE AS OF CHANGE: 20231004 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sigyn Therapeutics, Inc. CENTRAL INDEX KEY: 0001642159 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472573116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55575 FILM NUMBER: 231308847 BUSINESS ADDRESS: STREET 1: 9190 W OLYMPIC BLVD # 263 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 BUSINESS PHONE: 619-368-2000 MAIL ADDRESS: STREET 1: 9190 W OLYMPIC BLVD # 263 CITY: BEVERLY HILLS STATE: CA ZIP: 90212 FORMER COMPANY: FORMER CONFORMED NAME: Reign Resources Corp DATE OF NAME CHANGE: 20200512 FORMER COMPANY: FORMER CONFORMED NAME: Reign Sapphire Corp DATE OF NAME CHANGE: 20150512 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 4, 2023

SIGYN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

333-204486

47-2573116

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2468 Historic Decatur Road
Suite 140
San Diego, California		92106
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 619.368.2000

Prior address and phone number:

2468 Historic Decatur Road, Suite 140
San Diego, CA		92106
(Address of principal executive offices)		(Zip Code)

619.353.0800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

On October 4, 2023, Sigyn Therapeutics, Inc. (the “Company”) issued a press release announcing a PCT patent submission to enhance chemotherapy delivery and reduce cancer treatment toxicity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 7.01 “Regulation FD Disclosure” and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated October 4, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SIGYN THERAPEUTICS, INC.

Date: October 4, 2023	By:	/s/ James A. Joyce
		James A. Joyce, Chairman and CEO

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity

OCTOBER 04, 2023 8:30AM EDT SAN DIEGO, CA, Oct. 04, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today disclosed the submission of a Patent Cooperation Treaty (PCT) application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY.”

The PCT submission is associated with medical technologies being advanced by Sigyn Therapeutics to enhance the clinical benefit of chemotherapeutic drugs administered to cancer patients. Among therapeutic technologies being developed by the Company are ChemoPrep^™and ChemoPure^™. Chemotherapy is the most commonly administered drug to treat cancer, the second leading cause of death in the United States. Despite utility across a broad-spectrum of cancers, there remains a critical need to optimize chemotherapy delivery as less than 5% of administered doses reach their tumor-site target.

ChemoPrep^™is being advanced to extract circulating molecules that restrict the tumor-site delivery of chemotherapy and induce an unresponsiveness to therapy (chemoresistance) associated with 90% of metastatic cancer deaths. The clinical intent of ChemoPrep^™ is to safely increase the tumor-site saturation of chemotherapeutic agents with reduced doses. Achievement of this objective will likely improve treatment outcomes yet reduce treatment toxicity and long-term health consequences associated with chemotherapy administration. Beyond the potential to increase survival and enhance patient quality of life, reduced dosing of chemotherapeutic agents may alleviate ongoing supply chain issues associated with nationwide shortages of chemotherapy.

Post infusion of chemotherapy, Sigyn Therapeutics designed ChemoPure^™ to extract off-target drug agents from the bloodstream as a means to further reduce patient toxicity.

The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. A PCT submission makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing multiple national or regional patent applications. However, the granting of patents remains under the control of the national or regional patent offices. Sigyn Therapeutics previously disclosed that a related provisional patent application was filed with the United States Patent and Trademark Office (“USPTO”).

About Sigyn Therapeutics™

Sigyn Therapeutics is a development-stage medical technology company headquartered in San Diego, California. The Company plans to become a clinical-stage organization through first-in-human studies of Sigyn Therapy, a blood purification technology to treat pathogen-induced disorders that are not addressed with FDA approved therapies. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, the leading cause of hospital deaths in the United States.

Sigyn Therapeutics also develops therapeutic technologies to enhance the performance of cancer therapies. Sigyn Therapeutics designed ChemoPrep^™to improve the tumor-site delivery of chemotherapeutic agents and reduce their toxicity. ChemoPure^™ extracts off-target chemotherapy from the bloodstream to further reduce treatment toxicity. ImmunePrep^™ is a novel commercialization platform to enhance efficacy of monoclonal antibodies (including cancer checkpoint inhibitors) and antibody drug-conjugates (ADCs).

To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “will,” “projections,” “estimate,” “potentially” or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company’s ability to clinically advance its therapeutic technologies in human studies required for market clearance, the Company’s ability to manufacture its therapeutic technologies, the Company’s ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and in the Company’s other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

CONTACT:

Sigyn Therapeutics, Inc.
Charlene Owen
Director of Operations
858-353-0800 x100
Charlene@SigynTherapeutics.com

EX-101.SCH 3 sigy-20231004.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 sigy-20231004_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sigy-20231004_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 04, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 04, 2023
Entity File Number	333-204486
Entity Registrant Name	SIGYN THERAPEUTICS, INC.
Entity Central Index Key	0001642159
Entity Tax Identification Number	47-2573116
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2468 Historic Decatur Road
Entity Address, Address Line Two	Suite 140
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92106
City Area Code	619
Local Phone Number	368.2000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true

XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642159 2023-10-04 2023-10-04 iso4217:USD shares iso4217:USD shares 0001642159 false 8-K 2023-10-04 SIGYN THERAPEUTICS, INC. DE 333-204486 47-2573116 2468 Historic Decatur Road Suite 140 San Diego CA 92106 619 368.2000 false false false false true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sigyntherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm sigy-20231004.xsd sigy-20231004_lab.xml sigy-20231004_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "SIGY", "nsuri": "http://sigyntherapeutics.com/20231004", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "sigy-20231004.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sigy-20231004_lab.xml" ] }, "presentationLink": { "local": [ "sigy-20231004_pre.xml" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 21 }, "report": { "R1": { "role": "http://sigyntherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sigyntherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-035700-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-035700-xbrl.zip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end